![Heather Bax](/newimages/folsm/person-profile/bmb/heather-bax.xe1adc714.png?f=webp)
Dr Heather Bax
Postdoctoral Research Fellow
Research interests
- Cancer
- Biomedical and life sciences
Contact details
Biography
Developing novel antibodies of the IgE class to target solid tumours. Supporting the first-in-class, first-in-man, Phase 1 clinical trial of MOv18 IgE (ClinicalTrials.gov Identifier: NCT02546921). Now funded by IGEM Therapeutics Ltd (www.igemtherapeutics.com). Research programs include pre-clinical development of IgE antibodies against ovarian, breast (including TNBC), melanoma and lung cancers.
Research
![tubes 1800 x 500 banner.](/newimages/folsm/hero-banner/tubes-1800-x-500-banner..x64b64d12.png?w=1584&h=440&crop=780,440,182,0&width=380&height=215&fit=crop&f=webp)
Cancer Antibody Discovery & Immunotherapy Group
The Cancer Antibody Discovery & Immunotherapy Group is led by Professor Sophia Karagiannis
News
Study shows promising results for immunotherapy targeting skin cancer
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
![Cancer cells](/newimages/folsm/main-article/scps/cancer-cells.x489f12c2.png?crop=780,440,0,5&f=webp)
Research
![tubes 1800 x 500 banner.](/newimages/folsm/hero-banner/tubes-1800-x-500-banner..x64b64d12.png?w=1584&h=440&crop=780,440,182,0&width=380&height=215&fit=crop&f=webp)
Cancer Antibody Discovery & Immunotherapy Group
The Cancer Antibody Discovery & Immunotherapy Group is led by Professor Sophia Karagiannis
News
Study shows promising results for immunotherapy targeting skin cancer
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
![Cancer cells](/newimages/folsm/main-article/scps/cancer-cells.x489f12c2.png?crop=780,440,0,5&f=webp)